Novel therapies targeting the myeloma cell and its bone marrow microenvironment

Seminars in Oncology

Volumn 28, Issue 6, 2001, Pages 607-612

  Hideshima, Teru ^a,b   Chauhan, Dharminder ^a,b   Podar, Klaus ^a,b   Schlossman, Robert L ^a,b   Richardson, Paul ^a,b   Anderson, Kenneth C ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEASOME INHIBITOR; PROTEIN P21; PROTEIN P27; PROTEIN P53; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW; CANCER INHIBITION; CANCER RESISTANCE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MULTIPLE MYELOMA; MYELOMA CELL; PARACRINE SIGNALING; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0035211881     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90033-8     Document Type: Article

References (41)

1. Novel therapeutic targets in multiple myeloma
2. Novel biologically-based therapies for myeloma
3. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
4. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
5. Thalidomide is an inhibitor of angiogenesis
6. Antitumor activity of thalidomide in refractory multiple myeloma
7. Thalidomide - A revival story
8. Free radical mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
9. Multiple myeloma cell adhesion induced interleukin-6 expression in bone marrow stroma cells involves activation of NFκB
10. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines
11. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade
12. Multiple myeloma: Increasing evidence for a multistep transformation process
13. Expression of vascular endothelial growth factor and its receptor in hematological malignancies
14. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subsets
15. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogs that are potent inhibitors of TNF-α
16. Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy
17. Adhesion of human multiple myeloma cell lines to bone marrow stromal cells stimulates vascular endothelial growth factor secretion: Therapeutic applications
18. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
19. Tumor cell expression of CD 59 is associated with resistance to CD20 serotherapy in B cell malignancies
20. How proteolysis drives the cell cycle
21. p53 dependent induction of apopotosis by proteasome inhibitors
22. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53
23. Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression
24. The ubiquitin proteasome pathway is required for processing the NFκB precursor protein and the activation of NFκB
25. Proteasome inhibition: A novel mechanism to combat asthma
26. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor
27. The proteasome inhibitor PS-341 in cancer therapy
28. Proteasome inhibitor PS-341 is effective as a anti-angiogenic agent in the treatment of human pancreatic carcinoma via the inhibition of NFκB and subsequent inhibition of vascular endothelial growth factor production
29. The proteasome pathway is required for cytokine induced endothelial leukocyte adhesion molecule expression
30. Role of NFκB in the rescue of multiple myeloma cells from glucocorticoid induced apoptosis by Bcl-2
31. The proteasome inhibitor PS 341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
32. Production of lymphotoxin, a bone resorbing cytokine, by cultured human myeloma cells
33. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma
34. Expression of interleukin-1 β and tumor necrosis factor a in plasma cells from patients with multiple myeloma
35. High producer haplotypes of tumor necrosis factor α and lymphotoxin a are associated with an increased risk of myeloma and have an improved progression free survival after treatment
36. A multiple cytokine and second messenger responsive element in the enhancer of the human interleukin-6 gene: Similarities with c-fos gene regulation
37. NFκB regulates VCAM-1 expression on fibroblast-like synoviocytes
38. The role of tumor necrosis factor α in the pathophysiology of multiple myeloma: Therapeutic applications
39. Vascular endothelial growth factor and interleukin- 6 in paracrine tumor stromal cell interactions in multiple myeloma
40. Vascular endothelial growth factor triggered signaling cascades mediating multiple myeloma cell growth and migration
41. Targeted therapies for multiple myeloma